SAMBa ITT – Reducing the Size of Clinical Trials Jonathan Bartlett SAMBa ITT 4 Strictly Confidential 31 st May 2016.

Slides:



Advertisements
Similar presentations
Phase II/III Design: Case Study
Advertisements

Breakout Session 4: Personalized Medicine and Subgroup Selection Christopher Jennison, University of Bath Robert A. Beckman, Daiichi Sankyo Pharmaceutical.
Sample Size And Power I Jean B. Nachega, MD, PhD Department of Medicine & Centre for Infectious Diseases Stellenbosch University
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
Industrial Careers Expo Dr Heather Bryson 10 October 2012 University of Sheffield.
1 Implementing Adaptive Designs in Clinical Trials: Risks and Benefits Christopher Khedouri, Ph.D.*, Thamban Valappil, Ph.D.*, Mohammed Huque, Ph.D.* *
Federal Institute for Drugs and Medical Devices | The Farm is a Federal Institute within the portfolio of the Federal Ministry of Health (Germany) How.
Statistical Analysis for Two-stage Seamless Design with Different Study Endpoints Shein-Chung Chow, Duke U, Durham, NC, USA Qingshu Lu, U of Science and.
Futility Analysis A Miscellany of Issues Professor Andy Grieve King’s College London © Andy Grieve.
Bayesian posterior predictive probability - what do interim analyses mean for decision making? Oscar Della Pasqua & Gijs Santen Clinical Pharmacology Modelling.
1 Frank Miller, AstraZeneca, Södertälje Estimating the interesting part of a dose-effect curve: When is a Bayesian adaptive design useful? Frank Miller.
A new group-sequential phase II/III clinical trial design Nigel Stallard and Tim Friede Warwick Medical School, University of Warwick, UK
Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI
Non-Experimental designs: Developmental designs & Small-N designs
Clinical Trials Hanyan Yang
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
Sample Size Determination
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Adaptive Designs for Clinical Trials
NMF 3/6/03 Susan Galbraith, MB BChir PhD Vice President Clinical Discovery Oncology & Immunology Phase 0 Trials Why aren’t they more widely used by industry?
Paul Duckett Brixham Environmental Laboratory Site Manager.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Phase II Trials in Oncology S. Gail Eckhardt, MD Lillian Siu, MD Brian I. Rini, M.D.
Causality Matters John Adler, Head of Biometrics & Information Science for Cardiovascular and Metabolics, AstraZeneca FMS Dec 2, 2013 Some examples from.
Bayesian Statistics in Clinical Trials Case Studies: Agenda
CME Disclosure Statement The North Shore LIJ Health System adheres to the ACCME's new Standards for Commercial Support. Any individuals in a position.
Taming EHR Data Using Semantic Similarity to Reduce Dimensionality
Adaptive designs as enabler for personalized medicine
Stefan Franzén Introduction to clinical trials.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
CLINICAL TRIALS IN NEW DRUG DEVELOPMENT Michael A Ross,M.D. President CPL Inc.
European Statistical meeting on Oncology Thursday 24 th, June 2010 Introduction - Challenges in development in Oncology H.U. Burger, Hoffmann-La Roche.
Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company.
Challenges of Bridging Studies in Biomarker Driven Clinical Trials May 19, MBSW Conference. Muncie, IN. Szu-Yu Tang, Chang Xu, Bonnie LaFleur May.
International Tax & Global Mobility: Improving Employee Experience & Maintaining Corporate Tax Compliance Helen Bradshaw, Global Share Plan Manager – AstraZeneca.
Privacy Symposium / HIPAA Summit
Bayesian Approach For Clinical Trials Mark Chang, Ph.D. Executive Director Biostatistics and Data management AMAG Pharmaceuticals Inc.
Quality Metrics - Gain or Pain
Reduce & Repeat Non-Clinical Statistics Conference 2014, Brugge October 2014 More Precise XC50s Using Fewer Wells (in vitro) and Fewer Animals (in vivo)
Reducing bottlenecks: Rare-purposing™ Action Duchenne, November 07, 2015 David Cavalla, CSO, Healx.
MPS/MSc in StatisticsAdaptive & Bayesian - Lect 101 Lecture 10 Bayesian sequential methods for phase III trials and some final thoughts 10.1 Example: a.
Date | Presenter Case Example: Bayesian Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide)
European Patients’ Academy on Therapeutic Innovation Principles of New Trial Designs.
Infusion Kit compatibility James Baker - CHAOTIC 2 nd November
SMART Trials for Developing Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Designs NCDEU, 2006.
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
SAMBa ITT – Portfolio Management Alun Bedding SAMBa ITT 4 Strictly Confidential 31 st May 2016.
Sample Size Estimation
Rui (Sammi) Tang Biostatistics Associate Director, Vertex
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Issues in Hypothesis Testing in the Context of Extrapolation
Frank Miller AstraZeneca, Södertälje, Sweden
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola 
Subhead Calibri 14pt, White
Tobias Mielke QS Consulting Janssen Pharmaceuticals
Jennifer Gauvin, Group Head and Director
The 3rd Stat4Onc Annual Symposium
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Statistics for Clinical Trials in Cancer Research
Pediatric Drug Development A Regulatory Perspective
Quantitative Decision Making (QDM) in Phase I/II studies
A Bayesian Design with Conditional Borrowing of Historical Data in a Rare Disease Setting Peng Sun* July 30, 2019 *Joint work with Ming-Hui Chen, Yiwei.
Quantitative Decision Making (QDM) in Phase I/II studies
How Should We Select and Define Trial Estimands
Assessing Similarity to Support Pediatric Extrapolation
Presentation transcript:

SAMBa ITT – Reducing the Size of Clinical Trials Jonathan Bartlett SAMBa ITT 4 Strictly Confidential 31 st May 2016

Why Reduce the Size of Clinical Trials To make drug development more efficient and ethical. Reduction in the size of a trial means improvement ethically and most cost effective. The cost of R&D is ever increasing with the number of approvals reducing. 2

Paul et al Nat Rev Drug Disc. 2010;9: The Cost of Drug Development Eli Lilly R&D Productivity Model

One way might be to combine trials Combine more than one pre-clinical experiment (Pre-Clinical) Combine single dose and multiple dose ascending studies (Phase I) Proof of concept and dose finding (Phase II) Seamless Phase II/II trials 4

Pre-Clinical Discovery Studies Address the 3Rs - Replacement, Reduction and Refinement Property of GlaxoSmithKline Experiment 1 Experiment 2 Experiment 3 Experiment 4 Decision Experiment 1 Experiment 2 Experiment 3 Experiment 4 Decision One big design

Typical looking First in Human Studies Single Ascending Dose – 7 doses in cohorts 3 D1 + 1 P 3 D2 + 1 P 3 D3 + 1 P 3 D4 + 1 P 3 D5 + 1 P 3 D6 + 1 P 3 D7 + 1 P Total n = 28 6 MD1 + 2 P 6 MD2 + 2 P 6 MD3 + 2 P Multiple Ascending Dose – 3 doses in cohorts Total n = 24 Dose Follow-Up

Typical looking Proof of Concept Study then Dose Finding in 2b POC – 1 doses versus placebo High dose n = 50 Placebo n = 50 Total n = 100 Dose finding Total n = 200 High dose n = 50 Mid dose n = 50 Low dose n = 50 Placebo n = 50

Proposal for First in Human and Proof of Concept/Dose Finding Study Design FIH POC/DF Repeat dose adaptive dose escalation study in a patient population but not the target (N=20) Adaptive repeat dose in target population (N = 120) Traditional Paradigm = N = 352 Lean Paradigm N = 140

DoseFollow-Up Analysis N=2 SD MD Combined SD and MD Study

Combined POC/DF Design Initial Randomisation Placebo (n = 30) (+historical data) Interim analysis at n = 60 Is Dose 5 (highest) better than placebo? Dose 4 (n = 60) Dose 3 (n = 60) Dose 2 (n = 60) Dose 1 (n = 60) Placebo (n = 30) (+historical data) Add arms to explore the dose response Stop No Yes Dose 5 (n = 30)

Seamless Phase II/III 11

Another way is to use historical control data A large proportion of studies compare an experimental arm with an existing treatment or placebo. Interest has increased on using historical information for the control arm. Opportunity: Reduce the need for excessive control patients – reducing the size of clinical trials. Threat: Need to be aware of when the current data and not consistent with the historical data. 12

Where might we use historical control data? Rare diseases Single arm trials Non-inferiority trials Exploratory trials (not the subject of this talk/discussion) 13

Some issues Lack of consistency between prior and trial data Selection bias in the historical data Inflation of type I error and/or reduced power Increase in MSE due to bias 14

15 Motivating Paper

16 Use of Historical Model (sometimes called Bayesian Augmented Control) The Bayesian Hierarchical model as outline in Viele et al (2014). If  0 is the logit of the response rate for the current study,  1-H is the logit of the response rate from H historical studies (H can = 1). We assume that: -  0,  1,  2,  3,  4………,  H ~ N( ,  2 ) - Where  g is the study to study standard deviation. This is the term which allows for the dynamic borrowing between the New Study and the historical data. - We allow priors for , and  2 -  ~N(  0,  0 ) and  2 ~ Inverse-Gamma( ,  )  2 a llows for the dynamic borrowing. The larger  2 the less the borrowing

Summary Two ideas for reducing the size of trials Combining trials Use of historical data It would be good to see what other ideas people have 17

Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0) , F: +44 (0) , 18